Cargando…
Aβ1-42 and Tau as Potential Biomarkers for Diagnosis and Prognosis of Amyotrophic Lateral Sclerosis
Amyotrophic lateral sclerosis (ALS) is the most common motor neuron disease, but its definitive diagnosis delays around 12 months. Although the research is highly active in the biomarker field, the absence of specific biomarkers for diagnosis contributes to this long delay. Another strategy of bioma...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7216266/ https://www.ncbi.nlm.nih.gov/pubmed/32326346 http://dx.doi.org/10.3390/ijms21082911 |
_version_ | 1783532379178008576 |
---|---|
author | Lanznaster, Débora Hergesheimer, Rudolf C. Bakkouche, Salah Eddine Beltran, Stephane Vourc’h, Patrick Andres, Christian R. Dufour-Rainfray, Diane Corcia, Philippe Blasco, Hélène |
author_facet | Lanznaster, Débora Hergesheimer, Rudolf C. Bakkouche, Salah Eddine Beltran, Stephane Vourc’h, Patrick Andres, Christian R. Dufour-Rainfray, Diane Corcia, Philippe Blasco, Hélène |
author_sort | Lanznaster, Débora |
collection | PubMed |
description | Amyotrophic lateral sclerosis (ALS) is the most common motor neuron disease, but its definitive diagnosis delays around 12 months. Although the research is highly active in the biomarker field, the absence of specific biomarkers for diagnosis contributes to this long delay. Another strategy of biomarker identification based on less specific but sensitive molecules may be of interest in clinical practice. For example, markers related to other neurodegenerative diseases such as Alzheimer’s disease (AD) could be fully explored. Here, we compared baseline levels of amyloidβ1-42 (Aβ1-42), total Tau, and phosphorylated-Tau (phospho-Tau) protein in the cerebrospinal fluid (CSF) of ALS patients to controls and correlated it with clinical parameters of ALS progression collected over 12 months. We observed increased levels of Aβ1-42 (controls: 992.9 ± 358.3 ng/L; ALS: 1277.0 ± 296.6 ng/L; p < 0.0001) and increased Aβ1-42/phospho-Tau ratio and Innotest Amyloid Tau Index (IATI) (both p < 0.0001). IATI and the phospho-Tau/total Tau ratio correlated positively with ALSFRS-R and weight at baseline. Multivariate analysis revealed that baseline ALSFRS-R was associated with Aβ1-42 and phospho-Tau/total Tau ratio (p = 0.0109 and p = 0.0013, respectively). Total Tau and phospho-Tau levels correlated negatively with ALSFRS-R variation at months 6 and 9, respectively (p = 0.02 and p = 0.04, respectively). Phospho-Tau/total Tau ratio correlated positively with ALSFRS-R variation at month 9 (p = 0.04). CSF levels of Aβ1-42 could be used as a complementary tool to ALS diagnosis, and total Tau and phospho-Tau levels may help establishing the prognosis of ALS. Further studies merit exploring the pathophysiological mechanisms associated with these markers. Despite their lack of specificity, phospho-Tau/total Tau and Aβ1-42 should be combined to other biological and clinical markers in order to improve ALS management. |
format | Online Article Text |
id | pubmed-7216266 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-72162662020-05-22 Aβ1-42 and Tau as Potential Biomarkers for Diagnosis and Prognosis of Amyotrophic Lateral Sclerosis Lanznaster, Débora Hergesheimer, Rudolf C. Bakkouche, Salah Eddine Beltran, Stephane Vourc’h, Patrick Andres, Christian R. Dufour-Rainfray, Diane Corcia, Philippe Blasco, Hélène Int J Mol Sci Article Amyotrophic lateral sclerosis (ALS) is the most common motor neuron disease, but its definitive diagnosis delays around 12 months. Although the research is highly active in the biomarker field, the absence of specific biomarkers for diagnosis contributes to this long delay. Another strategy of biomarker identification based on less specific but sensitive molecules may be of interest in clinical practice. For example, markers related to other neurodegenerative diseases such as Alzheimer’s disease (AD) could be fully explored. Here, we compared baseline levels of amyloidβ1-42 (Aβ1-42), total Tau, and phosphorylated-Tau (phospho-Tau) protein in the cerebrospinal fluid (CSF) of ALS patients to controls and correlated it with clinical parameters of ALS progression collected over 12 months. We observed increased levels of Aβ1-42 (controls: 992.9 ± 358.3 ng/L; ALS: 1277.0 ± 296.6 ng/L; p < 0.0001) and increased Aβ1-42/phospho-Tau ratio and Innotest Amyloid Tau Index (IATI) (both p < 0.0001). IATI and the phospho-Tau/total Tau ratio correlated positively with ALSFRS-R and weight at baseline. Multivariate analysis revealed that baseline ALSFRS-R was associated with Aβ1-42 and phospho-Tau/total Tau ratio (p = 0.0109 and p = 0.0013, respectively). Total Tau and phospho-Tau levels correlated negatively with ALSFRS-R variation at months 6 and 9, respectively (p = 0.02 and p = 0.04, respectively). Phospho-Tau/total Tau ratio correlated positively with ALSFRS-R variation at month 9 (p = 0.04). CSF levels of Aβ1-42 could be used as a complementary tool to ALS diagnosis, and total Tau and phospho-Tau levels may help establishing the prognosis of ALS. Further studies merit exploring the pathophysiological mechanisms associated with these markers. Despite their lack of specificity, phospho-Tau/total Tau and Aβ1-42 should be combined to other biological and clinical markers in order to improve ALS management. MDPI 2020-04-21 /pmc/articles/PMC7216266/ /pubmed/32326346 http://dx.doi.org/10.3390/ijms21082911 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Lanznaster, Débora Hergesheimer, Rudolf C. Bakkouche, Salah Eddine Beltran, Stephane Vourc’h, Patrick Andres, Christian R. Dufour-Rainfray, Diane Corcia, Philippe Blasco, Hélène Aβ1-42 and Tau as Potential Biomarkers for Diagnosis and Prognosis of Amyotrophic Lateral Sclerosis |
title | Aβ1-42 and Tau as Potential Biomarkers for Diagnosis and Prognosis of Amyotrophic Lateral Sclerosis |
title_full | Aβ1-42 and Tau as Potential Biomarkers for Diagnosis and Prognosis of Amyotrophic Lateral Sclerosis |
title_fullStr | Aβ1-42 and Tau as Potential Biomarkers for Diagnosis and Prognosis of Amyotrophic Lateral Sclerosis |
title_full_unstemmed | Aβ1-42 and Tau as Potential Biomarkers for Diagnosis and Prognosis of Amyotrophic Lateral Sclerosis |
title_short | Aβ1-42 and Tau as Potential Biomarkers for Diagnosis and Prognosis of Amyotrophic Lateral Sclerosis |
title_sort | aβ1-42 and tau as potential biomarkers for diagnosis and prognosis of amyotrophic lateral sclerosis |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7216266/ https://www.ncbi.nlm.nih.gov/pubmed/32326346 http://dx.doi.org/10.3390/ijms21082911 |
work_keys_str_mv | AT lanznasterdebora ab142andtauaspotentialbiomarkersfordiagnosisandprognosisofamyotrophiclateralsclerosis AT hergesheimerrudolfc ab142andtauaspotentialbiomarkersfordiagnosisandprognosisofamyotrophiclateralsclerosis AT bakkouchesalaheddine ab142andtauaspotentialbiomarkersfordiagnosisandprognosisofamyotrophiclateralsclerosis AT beltranstephane ab142andtauaspotentialbiomarkersfordiagnosisandprognosisofamyotrophiclateralsclerosis AT vourchpatrick ab142andtauaspotentialbiomarkersfordiagnosisandprognosisofamyotrophiclateralsclerosis AT andreschristianr ab142andtauaspotentialbiomarkersfordiagnosisandprognosisofamyotrophiclateralsclerosis AT dufourrainfraydiane ab142andtauaspotentialbiomarkersfordiagnosisandprognosisofamyotrophiclateralsclerosis AT corciaphilippe ab142andtauaspotentialbiomarkersfordiagnosisandprognosisofamyotrophiclateralsclerosis AT blascohelene ab142andtauaspotentialbiomarkersfordiagnosisandprognosisofamyotrophiclateralsclerosis |